MarketResearchReports.com: Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives), New Report Launched

Novel Prophylactic and Therapeutic Approaches to Manage Staphylococcus aureus (S. aureus) Infections

Staphylococcus aureus disease is the leading cause of surgical site infections and infections that arise within hospital Intensive Care Units. Despite a clear and growing medical need, the pipeline for new antibiotics is drying up. Many pharmaceutical companies have abandoned antimicrobial research. In the meantime, bacteria are becoming more resistant to current antibiotics, with fewer new drugs being approved.

The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Staphylococcus aureus infections as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest . Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.

Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While anti-staphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development. More targeted and improved antibiotics are also in development.

The report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 92 pages, “Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)” report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines and small molecules for prevention and  treatment of Staphylococcus aureus infections. For more information visit:  http://www.marketresearchreports.com/la-merie-publishing/competitor-analysis-staphylococcus-aureus-vaccines-and-therapeutics-antibodies

In addition to covering the S. aureus Vaccines, S. aureus Antibodies, S. aureus Antibiotics, S. aureus Antiseptics & Anti-Infectives, Corporate S. aureus Vaccines & Therapeutics R&D Pipelines.

Find all Pharmaceuticals and Healthcare reports under a single page

Find all Therapeutic reports under a single page at: http://www.marketresearchreports.com/therapeutic

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

MarketResearchReports.com: The Engineered T-Cell Receptor in Fusion Proteins, Antibodies and Cells: Emerging Opportunities for the Biopharmaceutical Industry, New Report Launched

A comparative analysis and assessment of TCR technologies, pipelines and companies from an industry perspective

Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.

Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.

The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner.  The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.

This report entitled, “The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry” published in Ocotber 2013 describes chances and pitfals in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.

Benefits from the report:

  • Identify players in the field, from industry and academia;
  • Find out which TCR technologies are valued by Big Pharma and Biotech;
  • Understand the value of intracellular antigens targeted by the TCR;
  • Recognize the challenges of TCR-based therapeutics and their solutions;
  • Learn which TCR-based therapeutics are attractive for partnering;
  • Find out which TCR therapeutic approaches are not yet tapped.

Spanning over 84 pages and 5 table, “The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry” report provides information on market overview, drivers and challenge, competition and key trends.

In addition to covering the The T-Cell Receptor, TCR Fusion Proteins, TCR-Like (TCRL) Antibodies, TCR-Transfected T-Cells, Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells, Tumor-Infiltrating Lymphocytes (TILs), Opportunity Analysis for TCR-based Products and Technologies, Corporate R&D Pipelines.

For more information visit: http://www.marketresearchreports.com/la-merie-publishing/engineered-t-cell-receptor-fusion-proteins-antibodies-cells-emerging

Find all Therapeutic reports under a single page

Find all Oncology reports under a single page at: http://www.marketresearchreports.com/oncology

About Market Research Reports, Inc.

Market Research Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.